GENSOUS, Noemie; LAZARO, Estibaliz; BLANCO, Patrick; RICHEZ, Christophe

doi:10.1080/1744666X.2023.2268284

Metadatos

Licencia de uso del documento

GENSOUS, Noemie
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]

LAZARO, Estibaliz

Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]

BLANCO, Patrick
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]

Idioma

Article de revue

Este ítem está publicado en

Expert Review of Clinical Immunology. 2024, vol. 20, n° 1, p. 21 – 30

Resumen en inglés

Type 1 interferons (IFNs) play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE) and various type I IFNs targeting therapeutic approaches have been developed. Anifrolumab, a monoclonal antibody that binds to the subunit 1 of the type I IFN receptor, has acquired considerable interest and has entered different clinical human trials willing to evaluate its efficacy and safety. Areas covered: This review summarizes the data obtained in phases 1, 2, and 3 clinical trials of anifrolumab for SLE patients. A focus is made on data of clinical efficacy and safety obtained in MUSE, TULIP-1 and TULIP-2 trials. Expert opinion/Commentary: Anifrolumab is a promising therapeutic option for patients with SLE, currently authorized for moderate-to-severe SLE. Extensive real-world use is now going to generate data required to gain experience on the type of patients who benefit the most from the drug, and the exact positioning of anifrolumab in the therapeutic plan.< Leer menos

Palabras clave en inglés

Anifrolumab

COVID-19

Biologics

Cutaneous lupus erythematosus

Herpes zoster

Systemic lupus erythematosus

Type I interferons

Metadatos

Compartir este ítem

Licencia de uso del documento

Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Centros de investigación